This information was published on 2026-03-14T00:09:31 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2594377 |
| (220) |
13 Oct 2025
|
| (511) (510) |
Class 5
Pharmaceutical and biopharmaceutical products and preparations for the medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction; Pharmaceutical and biopharmaceutical products and preparations used for the treatment of cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; Pharmaceuticals used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; Biological preparations in the nature of microorganisms used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases. |
| (540) | MAAT PHARMA |
| (550) | Word |
| (730) |
MAAT PHARMA
|
| (750) |
Davies Collison Cave Pty Ltd
|
Find out more about publications on the About page.